Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't think they have the combination data yet. When they submit the abstract, they need to have the data in hand.
Totally agree.
My assumption is that usually the data present in any meeting should not be presented previously somewhere else.
Question for Zoriden. I found it from Yahoo message board "ASGCT 17th Annual Meeting May 19th to 24th, Richard Heller, PhD Non-Viral Gene Transfer of pIL-12 for the Treatment of Melanoma: Results from Phase I and II Clinical Trials". I assume this is the results from ONCS' Phase I and II trials on melanoma. Since ONCS also submitted an abstract to ASCO, is it logical to assume that the ASCO abstract is related to data on MCC (not melanoma)? Thanks in advance for your comment.
I agree. If they present the data on MCC instead of melanoma, it will be on the higher end you predicted.
Well said.
Zoriden, great post. Just a thought. Have you ever think of submitting it to Seeking Alpha? It will be a great exposure for ONCS.
Thanks for the clarification.
Question to the Longs. In today's article from Seeking Alpha titled "The REAL Inovio Pharmaceuticals: An Interview With Dr. J. Joseph Kim, CEO". Dr. Kim mentioned in the Q & A and said "We look forward to taking VGX-3100 and starting two new clinical studies for HPV-related diseases: cervical cancer and head and neck cancer. We will be adding a DNA-based cytokine, IL-12, and look forward to assessing this approach in a clinical setting". I thought ONCS obtained the exclusive licensing right of using IL 12 from INO. Anybody care to comment.
Hi Zoriden:
Do you have any information if they submit any abstracts to ASCO or AACR?
Thanks
Dr. Pierce answered a lot of questions about hugh potential of the combination of IL12 and Anti-PD-1. In addition, he also clearly explained the reason he came to ONCS. For everyone, you are crazy if you don't load up ONCS.
Lasers, well said. The 2 compounds from GSK are small molecule kinase inhibitors. Like most of the small molecule kinase inhibitors, they will work for awhile and the cancer cells will have mutations and render the molecules ineffective.
This question is for Zoriden, trebor4 or other posters who would like to respond. Recently, Dr. Pierce was hired by ONCS as CMO (previous from Merck). He has the expertise in anti-PD1 therapy. Last month, Dr. Kim from INO also mentioned about the importance of PD-1 inhibitors in cancer immunotherapy and implicated their involvement in that area. With the relationship between INO and ONCS and their history with Merck, is there a possibility INO and ONCS will join force and partner with a big pharma (perhaps Merck) in that area?
Zoriden:
I totally agree with you. I have bought and sold ONCS before when it was between 0,20 - 0,30. Luckily I decided to load it up a month ago when it was 0.28 and I am going to stay long from now on when you can see the bright future of this company.
What news? There is absolutely no news. It is strictly MM manipulation so they can buy more shares.
I don't mind he posted all the technical analysis. I believe he has a hidden agenda to persuade the other people to sell so he can get back in. This is unacceptable to me.
Don't forget the announcement of partnership(s) can be out before all the clinical data.
Thanks! I was aware of that publication. Novartis used INO electroporation technology. I was hoping INO would have the press release of that paper but I think it was Norvatis' call to release the information. It will be nice if the form a formal partnership.
Who are the collaborators of INO on RSV vaccine?
In this situation, I will take $ 8 a share.
The sad thing is the PPS and vol are going in the wrong direction.
I would say forget about the video. Ask him what is going on with ATRS. How come the volume is so low with only 7 weeks from the approval date?
There are at least 2 articles published the last 7 days. I think they are waiting for the conference before they release the news.
Sorry I am new to investing. Could somebody explain (or give comments) about the ATRS October 19th trading.How is it going to affect pps? Thanks
What is happening? There is a nice article published today and nobody has any comments. Where is everybody? No wonder is flat for quite awhile.